You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ROS-1 rearranged NSCLC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)

Recruiting
  • Nonsmall Cell Lung Cancer
  • Goyang-Si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

NSCLC (NSCLC) Trial in Boston (Lorlatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 7, 2021

Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

Withdrawn
  • Non-Small Cell Lung Cancer
  • InVisionFirst-Lung ctDNA assay
  • Los Angeles, California
  • +2 more
Sep 16, 2022

First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous

Recruiting
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Mar 1, 2022

Tolerance of Brigatinib in Management of Rearranged CBNPC ROS1

Completed
  • Lung Cancer ROS Translocated
    • Créteil, France
      CHI Créteil
    Nov 19, 2021

    NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

    Terminated
    • Non-small Cell Lung Cancer
    • Davis, California
    • +1 more
    Dec 22, 2022

    Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,

    Recruiting
    • Lung Cancer
    • +6 more
    • Boston, Massachusetts
    • +1 more
    Mar 7, 2021

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Department of Thoracic Surgery and Oncology, The First Affiliate
    Mar 17, 2023

    NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

    Not yet recruiting
    • Non-Small Cell Lung Cancer(NSCLC)
    • WX-0593 Tablets
    • Jinan, Shandong, China
      Shandong Cancer Hospital and Institute
    Mar 1, 2023

    NSCLC (NSCLC) Trial in Jinan (WX-0593 Tablets, chemo, Thoracic Radiation Therapy(TRT))

    Recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • WX-0593 Tablets
    • +2 more
    • Jinan, Shandong, China
      Shandong Cancer Hospital and Institute
    Apr 24, 2022

    ALK or ROS1-positive NSCLC Trial in China (Crizotinib)

    Active, not recruiting
    • ALK or ROS1-positive NSCLC
    • Fuzhou, Fujian, China
    • +9 more
    Aug 30, 2022

    Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

    Recruiting
    • Nsclc
    • +5 more
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 25, 2021

    Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Worldwide (NVL-520)

    Recruiting
    • Locally Advanced Solid Tumor
    • Metastatic Solid Tumor
    • Orange, California
    • +18 more
    Oct 6, 2022

    Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

    Recruiting
    • Non Small Cell Lung Cancer
    • anti-PD-1 or anti-PD-L1
    • +2 more
    • Shanghai, China
      Oncology Department, Shanghai Chest Hospital
    Jul 26, 2022

    Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

    Recruiting
    • Locally Advanced Lung Non-Small Cell Carcinoma
    • +9 more
    • Duarte, California
    • +4 more
    Aug 17, 2022

    Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Tumor-infiltrating Lymphocytes (TIL)
    • +5 more
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 28, 2022

    PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

    Recruiting
    • Non Small Cell Lung Cancer
      • Changsha, Hunan, China
        Yongchang Zhang
      Mar 9, 2022

      ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

      Terminated
      Has Results
      • ALK-positive Non-small Cell Lung Cancer (NSCLC)
      • +2 more
      • Irvine, California
      • +3 more
      Aug 30, 2021

      NSCLC Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1) Trial in Boston (SBRT with protons or photons)

      Active, not recruiting
      • Non-small Cell Lung Cancer Metastatic
      • Targetable Oncogenes (EGFR, ALK, ROS1)
      • SBRT with protons or photons
      • Boston, Massachusetts
        Massachusetts General Hospital
      Dec 22, 2021

      Breast Cancer, Cholangiocarcinoma, Colorectal Cancer Trial in Worldwide (Entrectinib)

      Recruiting
      • Breast Cancer
      • +15 more
      • Goodyear, Arizona
      • +146 more
      Aug 24, 2022

      NSCLC Trial in Guangzhou (TGRX-326)

      Recruiting
      • Non-small Cell Lung Cancer
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Jun 29, 2022

      NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

      Terminated
      • Non-small Cell Lung Cancer
      • +2 more
      • Brussels, Belgium
      • +18 more
      Aug 23, 2022

      Non-Small-Cell Lung Cancer, NSCLC Trial in Nagoya, Barcelona, Taipei (Lorlatinib)

      Recruiting
      • Non-Small-Cell Lung Cancer
      • NSCLC
      • Nagoya, Aichi, Japan
      • +2 more
      Jul 21, 2022

      Safety and Efficacy of Xalkori ROS1

      Recruiting
      • Non-small Cell Lung Cancer
      • Tokyo, Japan
        Pfizer local country office
      Aug 26, 2021